Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 4, 1998, Pages 787-796

  Komaki, Ritsuko ^a   Milas, Luka ^a   Ro, Jae Y ^a   Fujii, Takashi ^a   Perkins, Penny ^a   Allen, Pamela ^a   Sikes, Charles R ^a   Mountain, Clifton F ^a   Ordonez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Non small cell lung cancer; Pathological N1; Prognostic factors

Indexed keywords

CELL DNA; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DNA CONTENT; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; APOPTOSIS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0031899930     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00898-5     Document Type: Article

References (49)

1. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J. Clin. 47:1997;5-27.
2. Mountain C. F. A new international staging system for lung cancer. Chest. 89:1986;225S-233S.
3. Effects of postop mediastinal radiation on completely resected stage II and Stage III epidermoid cancer of the lung. N. Engl. J. Med. 315:1986;1377-1381.
4. Greco F. A., Hainsworth J. D., Cannon A. Multidisciplinary approach to dpotentially curable nonsmall cell lung cancer. Oncology. 11:1997;27-36.
5. Komaki R. Combined chemotherapy and radiation therapy in surgically unresectable regionally advanced nonsmall cell lung cancer. Semin. Radiat. Oncol. 6:1996;86-91.
6. Komaki R., Fujii T., Perkins P., Ro J. Y., Allen P. K., Mason K. A., Mountain C. F., Milas L. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;601-605.
7. Cibas E. S., Melamed M. R., Zaman M. B., Kimmel M. The effect of tumor size and tumor cell DNA content on the survival of patients with Stage I adenocarcinoma of lung. Cancer. 63:1989;1552-1556.
8. Fontanini G., Bigini D., Vignati S., Macchiarini P., Pepe S., Angeletti C. A., Pingitore R., Squartini F. p53 expression in nonsmall cell lung cancer clinical and biological correlations . Anticancer Res. 13:1993;737-742.
9. Kawai T., Suzuki M., Kono S., Shinomiya N., Rokutanda M., Takagi K., Ogata T., Tamai S. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Cancer. 74:1994;2468-2475.
10. Rice T. W., Bauer T. W., Gephardt G. N., Medendorp S. V., McLain D. A., Kirby T. J. Prognostic significance of flow cytometry in nonsmall-cell lung cancer. J. Thorac. Cardiovasc. Surg. 106:1993;210-217.
11. Fontanini G., Macchiarini P., Pepe S., Ruggiero A., Hardin M., Bigini D., Vignati S., Pingitore R., Angeletti C. A. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative nonsmall cell lung cancer. Cancer. 70:1992;1520-1527.
12. Harpole D. H., Herndon J. E., Wolfe W. G., Iglehart J. D., Marks J. R. A prognostic model of recurrence and death in stage I nonsmall cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.
13. Pence J. C., Kerns B-J. M., Dodge R. K., Iglehart D. Prognostic significance of the proliferation index in surgically resected nonsmall cell lung cancer. Arch. Surg. 128:1993;1382-1390.
14. Scagliotti G. V., Micela M., Gubetta L., Leonardo E., Cappia S., Borasio P., Pozzi E. Prognostic significance of Ki-67 labelling in resected nonsmall cell lung cancer. Eur. J. Cancer. 29A:1993;363-365.
15. Soomro I., Whimster W. F. Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with Ag NOR scores. J. Pathol. 162:1990;217-222.
16. Tirindelli-Danesi D., Teodori L., Mauro F., Modini C., Botti C., Cicconetti F., Stipa S. Prognostic significance of flow cytometry in lung cancer A 5-year study . Cancer. 60:1987;844-851.
17. Lee J. S., Ro J. Y., Sahin A. A., Hong K., Brown B. W., Mountain C. F., Hittelman W. K. Expression of blood-group antigen A A favourable prognostic factor in nonsmall cell lung cancer . N. Engl. J. Med. 324:1991;1084-1090.
18. Miyaki M., Taki T., Hitomi S., Hakomori S. Correlation of expression of H/Ley/b antigens with survival in patients with carcinoma of the lung. N. Engl. J. Med. 327:1992;14-18.
19. Carbone D. P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J. A., McIntire D., Slamon D., Gazdar A., Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected nonsmall cell lung cancer A preliminary report of LCSG 871 . Chest. 106:1994;377S-381S.
20. Casson A. G., McCuaig S., Craig J., Ayed A., Inculet R., Kerkvliet N., O'Malley F. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer a prospective study . J. Surg. Oncol. 56:1994;13-20.
21. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R., Takahashi T. Prognostic significance of p53 mutations and 3p deletions in primary resected nonsmall cell lung cancer. Anticancer Res. 53:1993;1-4.
22. Lee J. S., Yoan A., Kalapurakal S. K., Ro J. Y., Lee J. J., Tu N., Hittelman W. N., Hong W. K. Expression of p53 oncoprotein in nonsmall cell lung cancer a favorable prognostic factor . J. Clin. Oncol. 13:1995;1893-1903.
23. Morkve O., Halvorsen O. J., Skjaerven R., Stangeland L., Gulsvik A., Laerum O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated nonsmall cell lung carcinomas. Anticancer Res. 13:1993;571-578.
24. Passlick B., Izbicki J. R., Haussinger K., Thetter O., Pantel K. Immunohistochemical detection of p53 protein not associated with a poor prognosis in nonsmall cell lung cancer. J. Thorac. Cardiovasc. Surg. 109:1995;1205-1211.
25. Rusch V., Klinstra D., Venkatraman E., Oliver J., Martini N., Gralla R., Kris M., Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced nonsmall cell lung cancer. Cancer Res. 55:1995;5038-5042.
26. Top B., Mooi W. J., Klaver S. G., Boerrigter L., Wisman P., Elbers H. R. J., Visser S., Rodenhuis S. Comparative analysis of p53 gene mutations and protein accumulation in human nonsmall cell lung cancer. Int. J. Cancer. 64:1995;83-91.
27. Guinee D. G. Jr, Travis W. D., Trivers G. E., De Benedetti V., Cawley H., Welsh J. A., Bennett W. P., Jett J., Colby T. V., Tazelaar H., Abbondanzo S. L., Pairolero P., Trastek V., Caporaso N. E., Liotta L. A., Harris C. C. Gender comparisons in human lung cancer analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression . Carcinogenesis. 16:1995;993-1002.
28. Niklinski J., Furman M. Clinical tumour markers in lung cancer. Eur. J. Cancer Prev. 4:1995;129-138.
29. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bc1-2 protein in nonsmall cell lung carcinoma. N. Engl. J. Med. 329:1993;690-694.
30. Stephens L. C., Hunter N. R., Ang K. K., Milas L., Meyn R. E. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat. Res. 135:1993;75-80.
31. Hsu S-M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques A comparison between ABC and unlabeled antibody (PAP) procedures . J. Histochem. Cytochem. 29:1981;577-580.
32. Miller K., Auld J., Jessup E., Rhodes A., Ashton-Key M. Antigen unmasking in formalin-fixed routinely processed paraffin wax-embedded sections by pressure cooking A comparison with microwave oven heating and traditional methods . Adv. Anatomic Pathol. 2:1995;60-64.
33. Hedley D. W., Friedlander M. L., Taylor I. W. Method for analysis of cellular DNA content of paraffin-embedded pathologic materials using flow cytometry. J. Histochem. Cytochem. 31:1983;1333-1335.
34. McLemore D. D., El-Naggar A. K., Stephens L. C., Jardine J. Modified methodology to improve flow cytometric DNA histograms from paraffin-embedded material. Stain Technol. 65:1990;279-291.
35. Barlogize B., Ghde W., Johnston D. A. Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res. 38:1978;3333-3339.
36. Cox D. R. Regression models and life tables. J. R. Stat. Assoc. 34B:1972;187-202.
37. Johnson B. E., Kelley M. J. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest. 102:1993;1S-3S.
38. Macchiarini P., Fontanini G., Hardin M. J., Chuancheih H., Bigini D., Vignati S., Pintiore R., Angeletti C. A. Blood vessel invasion by tumor cells predicts recurrence in complete resected T1N0M0 nonsmall cell lung cancer. J. Thorac. Cardiovasc. Surg. 106:1993;80-88.
39. Meyn R. E., Stephens L. C., Ang K. K., Hunter N. R., Brock W. A., Milas L., Peters L. J. Heterogeneity in the development of apoptosis in irradiated murine tumors of different histologies. Int. J. Radiat. Biol. 64:1993;583-591.
40. Meyn R. E., Stephens L. C., Hunter N. R., Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs. 6:1995;443-450.
41. Milross C. G., Mason K. A., Hunter N. R., Chung W. K., Peters L. J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1996;1308-1314.
42. Chyle B., Pollack A., Bzerniak B., Stephens L. C., Zagars G. K., Terry N. H. A., Myen R. E. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;281-287.
43. Wheeler J. A., Stephens L. C., Tornos C., Eifel P. J., Ang K. K., Milas L., Allen P. K., Meyn R. E. Apoptosis as a predictor of tumor response to radiation in Stage IB cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;1487-1493.
44. Aihara M., Scardino P. T., Truong L. D., Wheeler T. M., Goad J. R., Yang G., Thompson T. C. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer. 75:1995;522-529.
45. Isobe H., Miyamoto H., Shimizu T., Haneda H., Hoshimoto M., Inoue K., Mizuno A., Kawakami Y. Prognostic significance of the flow cytometric nuclear DNA content in nonsmall cell lung cancer. Cancer. 65:1990;1391-1395.
46. Sahin A. A., Ro J. Y., El-Naggar A. K., Lee J. S., Ayala A. G., Teague K., Hong W. K. Flow cytometric analysis of the DNA content of nonsmall cell lung cancer. Cancer. 65:1990;530-537.
47. Straks G. M., Kwiatkowski D. J., Harpole D. H., Lynch T. J., Skarin A. T., Sugarbaker D. J. Molecular and pathologic markers in Stage I nonsmall-cell carcinoma of the lung. J. Clin. Oncol. 13:1995;1265-1279.
48. Volm M., Mattern J., Muller T., Drings P. Flow cytometry of epidermoid lung carcinomas relationship of ploidy and cell cycle phases to survival: a five-year follow-up study . Anticancer Res. 8:1988;105-112.
49. Volm M., Drings P., Mattern J., Sonka J., Vogt-Moykopf I., Wayss K. Prognostic significance of DNA patterns and resistance-predictive tests in nonsmall cell lung carcinoma. Cancer. 56:1985;1396-1403.